Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

about

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

Item

http://www.wikidata.org/entity/Q48629219

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

@en

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

@nl

type

Item

label

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

@en

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

@nl

prefLabel

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

@en

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

@nl

P1476

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

@en

P2093

Herbert A Vargas

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Matthew J O'Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Sean M McBride

http://www.w3.org/2001/XMLSchema#string

P2860

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

Tumor self-seeding by circulating cancer cells

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Integrative clinical genomics of advanced prostate cancer.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

P2888

nrclinonc.2017.160

P304

168-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2017.160

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Min Y Teo

P577

2017-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092241745

http://www.w3.org/2001/XMLSchema#string

P698

29039422

http://www.w3.org/2001/XMLSchema#string

P932

6652207

http://www.w3.org/2001/XMLSchema#string